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CD95  predominantly  acts  as  a  death  receptor 
when cross-linked with its CD95 ligand (CD95L) 
using a well-characterized pathway. Upon ligand 
binding, Fas-associated death domain associates 
with CD95, followed by recruitment of the initi-
ator caspase-8 to form the death-inducing signal-
ing complex. Caspase-8 oligomerization initiates 
its autocatalytic cleavage, followed by the release 
of active caspase fragments into the cytosol, sub-
sequent activation of effector caspases, DNA frag-
mentation, and cleavage of cellular substrates (1). 
Together with the Bcl-2 homology 3–only mol-
ecule Bcl-2–interacting mediator of death, the 
CD95/CD95L system contributes to the deletion 
of activated T cells during the termination phase 
of an immune response (2–4). Although the 
CD95/CD95L system plays a key role in T cell 
apoptosis  and  immunohomeostasis  as  indicated 
by the phenotype of lymphoproliferation mice 
and the induction of autoimmunity and lympho-
proliferation in patients with mutations in either 
the receptor or the ligand (5), CD95 mediates   
additional functions apart from cell death induc-
tion, including amplification of T cell prolifer-
ation upon co-stimulation with suboptimal doses 
of anti-CD3 antibodies (6–8). Nonapoptotic 
functions of CD95 have also been identified for 
cells of the central nervous system promoting 
neuronal development, growth, differentiation, 
and regeneration (9, 10). CD95 has also been re-
ported to induce tumor growth in lung, thyroid, 
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CD95 is a multifunctional receptor that induces cell death or proliferation depending on 
the signal, cell type, and cellular context. Here, we describe a thus far unknown function of 
CD95 as a silencer of T cell activation. Naive human T cells triggered by antigen-presenting 
cells expressing a membrane-bound form of CD95 ligand (CD95L) or stimulated by anti-
CD3 and -CD28 antibodies in the presence of recombinant CD95L had reduced activation 
and proliferation, whereas preactivated, CD95-sensitive T cells underwent apoptosis. Trig-
gering of CD95 during T cell priming interfered with proximal T cell receptor signaling by 
inhibiting the recruitment of -chain–associated protein of 70 kD, phospholipase-, and 
protein kinase C- into lipid rafts, thereby preventing their mutual tyrosine protein phos-
phorylation. Subsequently, Ca2+ mobilization and nuclear translocation of transcription 
factors NFAT, AP1, and NF-B were strongly reduced, leading to impaired cytokine secre-
tion. CD95-mediated inhibition of proliferation in naive T cells could not be reverted by the 
addition of exogenous interleukin-2 and T cells primed by CD95 co-stimulation remained 
partially unresponsive upon secondary T cell stimulation. HIV infection induced CD95L 
expression in primary human antigeen-presenting cells, and thereby suppressed T cell 
activation, suggesting that CD95/CD95L-mediated silencing of T cell activation represents 
a novel mechanism of immune evasion.
© 2009 Strauss et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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signaling events. We also demonstrate that HIV-1 infection ef-
ficiently induced CD95L surface expression in infected macro-
phages and dendritic cells, and that antigen-loaded, CD95L- 
expressing macrophages prevent activation of Jurkat cells. Our 
data suggest a new function of CD95 as a silencer of T cell acti-
vation, and CD95L expression on APCs might represent a novel 
mechanism of viral immune evasion and tolerance induction.
RESULTS
m-CD95L–expressing APCs prevent T cell activation  
and proliferation
CD95 sensitivity in human T cells depends on their activation 
status. Although naive T cells are CD95 resistant, CD95 sensi-
tivity develops 6–7 d after T cell activation (26). We have pre-
viously shown that expression of a noncleavable m-CD95L 
and HLA-A1 on APCs efficiently prevents development of 
HLA-A1–specific T cells in long-term T cell cultures in vitro 
(25). In this study, we analyze whether CD95L-expressing 
APCs in fact delete antigen-specific T cells or whether CD95 
triggering instead prevents antigen-specific T cell priming in 
naive T cells. Therefore, we stimulated CFSE-labeled HLA-
A1 T cells with the lymphoblastoid cell line C1R.A1.CD95L 
expressing the alloantigen HLA-A1 and m-CD95L (25). As 
controls, we used mock transfectant (C1R.A1.puro; HLA-
A1+ and m-CD95L) or medium. Activation by HLA-A1 in 
the absence of m-CD95L (C1R.A1.puro) induced T cell pro-
liferation in CD4+ and CD8+ T cells starting at day 6. Prolifer-
ation of CD4+ T cells is caused by the expression HLA-Cl II 
antigens by the stimulator cells. In contrast, the presence of   
m-CD95L (C1R.A1.CD95L) abolished proliferation in both 
T cell subsets (Fig. 1 A). Inhibition of proliferation by CD95L 
was associated with a significant reduction in the expression of 
activation markers on CD4+ and CD8+ T cells at day 6, when 
the first T cell divisions were detectable (Fig. 1 B). The secre-
tion of the Th1-specific cytokines IFN- and IL-2 was strongly 
reduced in the presence of m-CD95L, and secretion of the 
Th2 cytokine IL-10 was totally impaired in T cells activated 
with C1R.A1.CD95L after 1, 3, and 5 d compared with   
T cells stimulated with the mock transfectant (Fig. 1 C). No sig-
nificant differences were detected for TNF-. These results 
demonstrate that the expression of m-CD95L on APCs im-
pairs T cell activation and proliferation.
Simultaneous triggering of CD95 and TCR induces  
apoptosis in activated human T cells and inhibits 
proliferation of naive T cells
HLA-A1–expressing APCs only activate alloantigen-specific 
T cells, which constitute 3–10% of total T cells. To stimulate 
T cells independently of antigen specificity, in our experi-
ments we substituted APCs with immobilized anti-CD3 and 
anti-CD28 antibodies in combination with plate-bound re-
combinant CD95L. Therefore, CFSE-labeled T cells were 
stimulated with immobilized anti-CD3 and anti-CD28 anti-
bodies in the absence (CD3/28) or presence of CD95L 
(CD3/28/95L). After 6 d, proliferation of T cells was effi-
ciently inhibited in the presence of CD95L compared with 
and ovarian cancer, and to trigger basal invasion of glioblas-
toma in vivo (11–13). T cells inhibited in caspase activation 
(8) or T cells deficient for Fas-associated death domain (14, 
15), caspase-8 (16, 17), or flice-like inhibitory protein (18) 
exhibited impaired T cell activation and proliferation, sug-
gesting an essential role for molecules downstream of the 
CD95 pathway in T cell activation.
T cell activation is initiated by binding of the TCR to the 
appropriate antigen presented by HLA molecules, followed by 
translocation of the TCR and its associated signaling molecules 
into lipid rafts, which are microdomains of the plasma mem-
brane enriched in cholesterol and glycosphingolipids. By in-
ducing close proximity of signaling molecules, rafts serve as 
signaling platforms (19, 20). Src family protein tyrosine kinases 
(lymphocyte-specific kinase and p59fyn) subsequently phos-
phorylate the immunoreceptor tyrosine-based activation mo-
tifs of the CD3 chains, followed by recruitment and activation 
of -chain-associated protein of 70 kD (ZAP-70). After phos-
phorylation by ZAP-70, the transmembrane adaptor linker of 
activated T cells (LAT) and the cytosolic adaptor protein SLP-76 
constitute docking proteins (e.g., for PLC-), which then   
hydrolyzes phosphatidylinositol 3,4-bisphophate into the sec-
ondary messengers inositol 1,4,5-triphosphate and diacylglyc-
erol to initiate Ca2+ influx and activation of protein kinase C- 
(PKC-) and the mitogen activated protein kinase (MAPK) 
cascade, finally resulting in the activation of transcription 
through NFAT, NF-B, and AP-1 (21). In contrast to TCR 
signaling, the requirement for lipid raft formation in CD95 
signaling is controversially debated. Although the association 
of CD95 with lipid rafts was reported to define the CD95 sen-
sitivity of T cells and to render activated T cells sensitive to 
apoptosis after TCR stimulation (22), no requirement for raft 
formation in CD95-mediated death was reported in a B cell 
line (23). Recent studies, however, suggest that molecules of 
the CD95 pathway, such as caspase-8 and the c-flice–like in-
hibitory proteinL, are essential components of rafts induced   
after TCR ligation and are associated with NF-B adaptors 
during T cell activation (24).
T cell activation and T cell death are tightly controlled pro-
cesses to guarantee both efficacy of the immune response and 
prevention of autoimmunity. Whether or not cells undergo 
apoptosis or start proliferation is defined by cell type, activation 
status, and co-stimulatory signals. We have previously shown 
that  APCs  expressing  a  membrane-bound  form  of  CD95L   
(m-CD95L) and the alloantigen HLA-A1 are able to prevent 
the outgrowth of HLA-A1–specific T cells in long-term T cell 
stimulation cultures and to efficiently induce apoptosis in pre-
activated CD95-expressing T cells (25), suggesting that HLA-
A1–specific T cells were deleted after antigen-specific priming 
by the CD95/CD95L system. In this study, we analyzed the ef-
fect of CD95 triggering during the activation of primary human 
T cells using CD95L-expressing APCs or anti-CD3 and anti-
CD28 antibodies together with recombinant CD95L. While 
activated, CD95-sensitive T cells underwent apoptosis, naive   
T cells were inhibited in proliferation, and CD95 triggering dur-
ing T cell priming directly interfered with early proximal TCR JEM VOL. 206, June 8, 2009 
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Because T cells used in this study were purified from human 
buffy coats and contained on average 30–50% preactivated, 
CD95-sensitive T cells, constitutive CD95 sensitivity may 
account for the observed high levels of apoptosis induction. 
Therefore, we purified naive T cells from the T cell pool by 
CD3/28-stimulated T cells (4 vs. 22%). Triggering of T cells 
with CD95L alone did not affect proliferation (0%). How-
ever, the presence of CD95L-induced apoptosis of 43–47% 
of nondividing T cells (Fig. 2 A). Thus, the lack of prolifera-
tion might be caused by an increase in apoptosis induction. 
Figure 1.  m-CD95L–expressing APCs prevent T cell activation and proliferation. Purified CFSE-labeled HLA-A1 T cells were stimulated with me-
dium, C1R.A1.puro (puro), or C1R.A1.CD95L (CD95L) cells. (A) After 6 and 10 d, T cells were counterstained for CD19, CD2, CD4, CD8, and 7-AAD. Stimula-
tor cells were excluded by gating on CD19 cells and blots represent proliferation and death induction in the different T cell subsets. (B) After 6 d, the 
expression of activation markers was determined in CD4+ and CD8+ T cell subsets. (C) After 1, 3, and 5 d, supernatants were analyzed for cytokine content. 
Cytokine expression in mitomycin c–treated stimulator cells or T cells alone was used as control. All data are representative of one experiment out of 
three. Values represent the mean of triplicates ± SD.1382 INHIBITION OF T CELL PRIMING BY CD95 CO-STIMULATION | Strauss et al.
from naive T cells compared with naive T cells stimulated 
with CD3/28 alone (Fig. 2 C). To test, whether the effi-
ciency in inhibition of T cell proliferation by CD95L is de-
pendent on the strength of the T cell activating stimulus, we 
stimulated naive CFSE-labeled T cells with increasing con-
centrations of immobilized anti-CD3 plus anti-CD28 anti-
bodies. CD95L completely prevented T cell proliferation in 
CD4+ and CD8+ T cells at all antibody concentrations tested 
(Fig. 3 A). At CD3/38 concentrations of 0.2 µg/ml T cells, 
proliferation is totally inhibited in the presence of CD95L 
compared  with  T  cells  stimulated  with  CD3/28  (CD2+: 
depleting cells expressing the activation markers CD25 and 
CD45RO. CFSE-labeled CD45ROCD25 T cells showed 
a significant inhibition of proliferating, live cells in the pres-
ence of CD95L compared with T cells stimulated with CD3/28 
(CD3/28 = 29% versus CD3/28/95L = 6%), whereas apop-
tosis induction was only moderately increased (CD3/28 = 
8% versus CD3/28/95L = 21%; Fig. 2 B). Although naive   
T cells are CD95 resistant, they express CD95 on the cell sur-
face; however, at lower levels than compared with activated 
T cells (Fig. S1). The presence of CD95L during T cell acti-
vation prevents secretion of Th1- and Th2-specific cytokines 
Figure 2.  Simultaneous triggering of CD95 and TCR induces apoptosis in activated T cells and inhibits proliferation and cytokine secretion of 
naive T cells. CFSE-labeled purified T cells (total T cells; A) or naive T cells (B) were stimulated with immobilized anti-CD3 and anti-CD28 mAb in the absence 
(CD3/28) or presence of CD95L (CD3/28/95L) or with medium or CD95L alone. After 6 d, T cells counterstained with PI were analyzed by flow cytometry.  
The experiment is representative of three experiments carried out. (C) Purified naive T cells were incubated with immobilized anti-CD3 and anti-CD28 mAb in  
the absence or presence of CD95L. Cytokine secretion was determined in the supernatants at different time points. Secretion of cytokines by T cells cultured  
in medium or on CD95L-coated plates alone was determined, but expression was below the detection level of the assay (0.5 pg/ml), and therefore not included 
into the graphs. Data are representative of one experiment out of two carried out. Values present the mean of triplicates ± SD.JEM VOL. 206, June 8, 2009 
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Figure 3.  Independent of the strength of the TCR- mediated signal, proliferation of naive T cells is prevented by CD95 co-stimulation and 
could not be reverted by IL-2. (A) CFSE-labeled naive T cells were incubated on plates coated with increasing amounts of anti-CD3 and anti-CD28 anti-
bodies in the absence (medium) or presence of CD95L. After 6 d, T cells were stained for CD2, CD4, CD8, and 7-AAD, and T cell proliferation and death 
induction were determined in the different T cell subsets. After 6 d of culture, cell recovery was 84% on average in medium-treated cells, 70% in CD95L, 
79% in 0.1 µg/ml CD3/28, 102% in 0.2 µg/ml CD3/28, 139% in 0.4 µg/ml CD3/28, 145% in 0.5 µg/ml CD3/28, 77% in 0.1 µg/ml CD3/28 + CD95L, 81% in 
0.2 µg/ml CD3/28 + CD95L, 78% in 0.4 µg/ml CD3/28 + CD95L, and 80% in 0.5 µg/ml CD3/28 + CD95L. (B) CFSE-labeled naive T cells were stimulated with 
immobilized anti-CD3 and anti-CD28 mAb (0.1 µg/ml) (CD3/28) or CD3/28 plus CD95L (CD3/28/95L), or medium or CD95L alone in the presence or  
absence of recombinant IL-2 (30 U/ml). After 5 d, cells were stained for CD2, and proliferation and cell death induction was determined for CD2+ T cells.  
All data are representative of one out of three experiments.1384 INHIBITION OF T CELL PRIMING BY CD95 CO-STIMULATION | Strauss et al.
Figure 4.  Co-stimulation of CD95 during T cell priming induces T cell unresponsiveness. Naive T cells were CFSE labeled and cultured on plates 
coated with anti-CD3 and anti-CD28 antibodies in the absence (CD3/28) or presence of CD95L (CD3/28/95L) or CD95L alone or medium. After 6 d, T cells 
were harvested and 2 × 105 cells of each stimulation group were stained with propidium iodide (PI) and analyzed by flow cytometry (day 6). The remain-
ing cells from each stimulation group were restimulated on 0.2 µg/ml CD3/28-coated plates in the presence or absence of 30 U/ml IL-2 or with 30 U/ml 
IL-2 alone or left untreated (medium). After 4 d, cells were harvested, stained with PI, and analyzed by flow cytometry (day 10). The experiment is repre-
sentative for one out of three experiments done.
CD3/28 = 30% versus CD3/28/95L = 2%), whereas apop-
tosis induction was not increased (CD2+: CD3/28 = 17% 
versus CD3/28/95L = 19%). At higher CD3/28 concentra-
tions, dividing T cells probably die because of a limited sup-
ply of IL-2, as assays were performed in the absence of 
exogenous IL-2. First cell divisions were measurable after day 
2 of T cell stimulation (unpublished data). Independent of 
whether isolated CD4+ and CD8+ T cells were activated sep-
arately or in co-culture, CD95 co-stimulation totally inhib-
ited their proliferation in both culture systems (Fig. S2). 
Because of the usage of T cells from different donors, we al-
ways observed slight differences in proliferation, apoptosis 
induction, and efficiency of inhibition. However, in all ex-
periments performed, CD95 co-stimulation significantly pre-
vents T cell proliferation between 80 and 100%. Interestingly, 
adding exogenous recombinant IL-2 could not reverse the 
inhibitory effect of CD95L on T cell activation. Although 
the addition of IL-2 efficiently enhanced proliferation in 
CD3/28-stimulated naive T cells, CD3/28/95L-stimulated 
T cells did not proliferate irrespective of the presence of IL-2 
(Fig. 3 B). No effect of IL-2 was observed in T cells cultured 
in medium or in the presence of CD95L alone. Membrane-
bound CD95L is cleaved by proteases from the cell surface 
(27), and soluble CD95L might interfere with the antiprolif-
erative effect of immobilized CD95L. However, the addition 
of soluble CD95L to our culture system did not prevent the 
inhibition of T cell proliferation induced by immobilized 
CD95L (Fig. S3). These results clearly show that T cell prim-
ing can be efficiently suppressed by CD95 co-stimulation.
CD95 triggering in combination with CD3/28 activation 
induces T cell unresponsiveness
Because CD95L prevents proliferation of CD3/28-activated 
naive T cells, we raised the question of whether T cell silenc-
ing requires the constitutive presence of CD95L in the T cell 
stimulation culture. We therefore activated naive T cells with 
CD3/28, in the absence or presence or CD95L, with CD95L 
or medium alone. After 6 d, 2 × 105 T cells of each stimulation 
group were analyzed (day 6). The presence of CD95L effi-
ciently prevented T cell proliferation compared with CD3/28-
stimulated T cells (Fig. 4). The remaining cells from each 
stimulation condition were restimulated with immobilized 
anti-CD3 and -CD28 antibodies in the presence or absence of 
IL-2, and proliferation was measured 4 d later (day 10). Re-
stimulation of previously CD3/28-activated, medium, or 
CD95L-stimulated T cells with anti-CD3 and anti-CD28 an-
tibodies induced efficient T cell proliferation (day 10). In con-
trast, the proliferation of T cells cultured for 6 d in the presence 
of CD3/28/95L and restimulated with CD3/28 was strongly 
reduced compared with T cells previously cultured in the JEM VOL. 206, June 8, 2009 
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Figure 5.  Inhibition of proximal TCR signaling events in T cells activated in the presence of CD95L. (A and B) Purified T cells were activated on 
plates coated with anti-CD3 and anti-CD28 antibodies in the absence or presence of CD95L. Expression of total protein tyrosine phosphorylation (pY; A) or of 
specific phosphorylated proteins (B) was determined by Western blot analysis at different time points. Arrows indicate differences in protein tyrosine phos-
phorylation. Experiments were performed three times with similar results. (C) Fluo-4 labeled T cells were seeded on poly-l-lysine–coated slides and antibodies 
were given to cells directly before the measurement. For measuring the intracellular calcium, a time series of one confocal image plane was recorded. Image 
acquisition was started immediately after applying the antibodies. After subtracting the background fluorescence, the mean of all cells at each time point was 
calculated. Each curve represents the mean of three independent experiments. (D) Purified naive T cells were activated with immobilized anti-CD3 plus anti-
CD28 antibodies in the presence or absence of CD95L. After 1 and 4 h, nuclear extracts were prepared and analyzed by EMSA for DNA-binding activity of 
NFAT, AP1, and NF-B. PMA/ionomycin stimulation served as a positive control. The experiment is representative of three different experiments performed.  
(E) Purified T cells stimulated with immobilized anti-CD3 and anti-CD28 mAb in the absence or presence of CD95L were lysed after 10, 30, 40, and 240 min, 
and lysates were subjected to Western blot analysis to determine the expression of phosphorylated and nonphosphorylated MAPKs (ERK1/2, p38, Jnk1/2).  
-Actin expression served as a loading control. The experiment shown is representative of two experiments done. (F) CFSE-labeled naive T cells were stimu-
lated with immobilized anti-CD3 and anti-CD28 mAb or with PMA and ionomycin in the absence (CD3/28, PMA/iono) or presence of CD95L (CD3/28/95L, 
PMA/iono/95L) or with medium or CD95L alone. After 5 d, T cells were stained with 7-AAD, CD2, CD4, and CD8 and analyzed by flow cytometry. Data present 
the percentage of proliferating, live (7-AAD) T cells in the different T cell subsets. Experiments were performed three times with similar results.1386 INHIBITION OF T CELL PRIMING BY CD95 CO-STIMULATION | Strauss et al.
presence of CD95L alone (12 vs. 38%). However, the sus-
tained inhibition of proliferation by CD95L was reversed by 
the addition of exogenous IL-2. In summary, these data indi-
cate  that  CD95  co-stimulation  of  CD3/28-activated  naive   
T cells induces an unresponsive state, which can be overcome 
by IL-2 after release from CD95L-mediated suppression.
T cells activated in the presence of CD95L exhibited 
impaired protein tyrosine phosphorylation, Ca2+ 
mobilization, mitogen-activated protein (MAP) kinase 
activation, and nuclear translocation of transcription factor
We next estimated whether CD95 co-stimulation would in-
terfere with early signaling events after TCR engagement. Af-
ter 5 min, CD3/28 stimulation induced a strong tyrosine 
phosphorylation of proteins with apparent molecular weights 
of 150, 70, and 40 kD, respectively, which was still detect-
able after 60 min and completely blocked in the presence of 
CD95L (Fig. 5 A). Western blot analysis using phosphospecific 
antibodies showed that the presence of CD95L during TCR 
triggering completely abolished the phosphorylation of LAT, 
ZAP-70, and phospholipase (PLC)-1 (Fig. 5 B). Triggering 
of CD95L alone did not induce protein tyrosine phosphoryla-
tion. Because of the lack of protein tyrosine phosphorylation, 
T cells activated with anti-CD3 and anti-CD28 antibodies in 
the presence of CD95L showed no Ca2+ influx compared with 
T cells activated with CD3/28 (Fig. 5 C). Inhibition of protein 
tyrosine phosphorylation and decreased Ca2+-influx was re-
flected by impaired nuclear translocation of transcription fac-
tors NF-B, AP1, and NFAT in CD3/28/95L-stimulated   
T cells compared with CD3/28- or PMA/ionomycin-activated 
T cells after 1 and 4 h of activation (Fig. 5 D). T cells stimu-
lated with CD95L alone exhibited no differences to untreated 
T cells. Also, mitogen-activated protein kinase (MAPK) acti-
vation known to be induced after TCR stimulation (28) was 
totally abolished in T cells activated in the presence of CD95L 
after 10, 30, 60, and 240 min (Fig. 5 E). Although phosphory-
lation of ERK1/2 and JNK1 was decreased after 30 min in 
CD3/28-activated samples, phosphorylation of p38 remained 
constant. Phosphorylation of JNK2 was constitutively inde-
pendent of the stimulus and CD95L treatment alone did not 
induce MAPK activation. To further prove that CD95 trigger-
ing during T cell activation interferes with proximal T cell re-
ceptor  events,  we  activated  naive  T  cells  with  PMA  and 
ionomycin known to directly activate PKC and Ca2+ mobili-
zation independent of TCR stimulation. Although CD3/28-
mediated T cell proliferation was completely blocked in the 
presence of CD95L, the proliferation induced by PMA/iono-
mycin treatment could not be inhibited (Fig. 5 F). In sum-
mary, we could show that proximal T cell receptor signaling is 
severely disabled by CD95 co-stimulation.
Co-stimulation of CD95 during T cell activation prevents 
caspase cleavage and formation of a functional  
signaling platform
Caspase activity is a hallmark of apoptosis induction, but   
also a prerequisite for T cell proliferation. CD3/28-mediated   
T cell proliferation was abrogated by the broad caspase inhibi-
tor Z-Val-Ala-DL-Asp-fluoromethylketone (z-VAD.fmk;   
Fig. 6 A). Cleavage of caspase-3, -8, and -10 was detected in 
CD3/28-stimulated total T cells (pool) or naive T cells iso-
lated from one buffy coat. Surprisingly, the presence of CD95L 
totally inhibited processing of all caspases examined (Fig. 6 B). 
No caspase cleavage was detected in T cells stimulated with 
CD95L alone or medium. To determine caspase activity, na-
ive T cells were incubated for 24 or 48 h with the cell per-
meable, rhodamine 110-based caspase substrates DEVD 
(Asp-Glu-Val-Asp; specific for caspase-3, -6, -7, -8, and -10) 
and Ile-Glu-Thr-Asp (IETD; specific for caspase-8 and gran-
zyme B). The presence of CD95L completely blocked CD3/28-
mediated caspase activity at both time points, whereas activation 
by CD95L alone or medium had no effect (Fig. 6 C). Despite 
caspase activation in CD3/28-treated T cells, no increase in 
PARP cleavage compared with untreated cells was observed 
(Fig. 6 B), suggesting that processed caspases might be se-
questered to special membrane compartments during T cell 
activation to prevent induction of apoptosis. Because TCR-
mediated signaling preferentially occurs within lipid rafts, we 
isolated lipid rafts by discontinuous sucrose gradient from   
T cells stimulated in the presence or absence of CD95L. West-
ern blot analysis using LAT as a raft marker and the cytoplas-
mic protein -tubulin as a nonraft marker identified fraction 
4–6 as raft and fraction 11 as nonraft (Fig. S4). CD3/28-acti-
vated T cells exhibited recruitment of PLC-, PKC-,   
and ZAP-70 into lipid rafts, whereas nontreated T cells did 
not. Importantly, triggering CD95 during T cell activation 
(CD3/28/95L) efficiently prevented recruitment of PLC-, 
PKC-, and ZAP-70 into the raft fraction (Fig. 6 D). Un-
treated T cells and CD95L-treated T cells exhibited no differ-
ence in the recruitment of T cell–associated molecules into 
lipid rafts (Fig. S5). Recruitment of the protein tyrosine phos-
phatase Scr homology-2 domain-containing phosphatase-1, 
which is known to be predominantly expressed in cells of the 
hematopoietic system and to function as a negative regulator   
of TCR-mediated signaling (29, 30), was not increased in the   
raft fraction of CD3/28/95L-activated T cells compared with 
CD3/28-treated T cells. Additionally, Scr homology-2 domain-
containing phosphatase-2 was not detectable in the raft fractions 
independent of the activating stimulus (Fig. 6 E). LAT constitu-
tively expressed in lipid rafts was detected in all raft fractions in-
dependent of the stimulation signal. Because caspase-8 is required 
for T cell and NF-B activation (16) and active caspases were 
reported to localize in lipid rafts in activated T cells (24, 31), we 
determined caspase-8 expression in the lipid raft fractions. The 
proform of caspase-8 (56/55) was found in all lipid raft fractions 
independent of the stimulus, whereas the intermediate cleavage 
product (p43/41) was only found in the raft fraction of CD3/28-
activated T cells (Fig. 6 D). In contrast to the finding that the 
presence of CD95L prevents caspase-8 cleavage (Fig. 6 B), we 
observed caspase-8 cleavage in the nonraft fraction of CD3/28/
95L-stimulated T cells (Fig. 6 D). However, in Fig. 6 D, T cells 
cultured in medium alone already showed a weak caspase-8 ac-
tivation, which was not increased in the presence of the CD95L JEM VOL. 206, June 8, 2009 
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CD95L up-regulation on APCs may constitute a mechanism 
of viral immune evasion
Inhibition of T cell proliferation caused by CD95 triggering 
during T cell priming may help invading pathogens to avoid 
activation. These differences are caused by varying T cell prepa-
rations derived from different donors. Collectively, these results 
clearly indicate that CD95 triggering during T cell activation 
prevents the formation of a functional signaling platform.
Figure 6.  CD95 triggering during T cell activation prevents caspase activation and translocation of TCR-associated molecules into lipid 
rafts. (A) CFSE-labeled naive T cells were activated with immobilized anti-CD3 plus anti-CD28 antibodies (CD3/28) in the presence of absence of Z-VAD.
fmk (50 µM). After 6 d, cells were stained with propidium iodide (PI) and analyzed by flow cytometry. (B) Purified T cells (pool) and naive T cells (naive) 
from one buffy coat were activated with immobilized anti-CD3 plus anti-CD28 mAb in the presence or absence of CD95L. After 24 h, cells were harvested 
and protein lysates were subjected to Western blot analysis. -Actin served as a loading control. (C) Naive T cells were activated with immobilized anti-
CD3 plus anti-CD28 antibody in the absence (CD3/28) or presence of CD95L (CD3/28/95L) or with medium or CD95L alone. After 24 and 48 h, cells were 
incubated with caspase substrates DEVD-D2R and IETD-D2R and caspase activity was determined by flow cytometry. (D and E) T cells were activated on 
anti-CD3 plus anti-CD28–coated plates in the absence (CD3/38) or presence of CD95L (CD3/28/95L) or with CD95L alone or medium. After 24 or 48 h, 
cells were harvested and lysed, and lysates were separated on a discontinuous sucrose gradient. Proteins from fraction 4–6 (raft fraction) and fraction 11 
(nonraft fraction) were analyzed by Western blot analysis. All data shown are representative of three independent experiments.1388 INHIBITION OF T CELL PRIMING BY CD95 CO-STIMULATION | Strauss et al.
Figure 7.  HIV-1 infection induces CD95L surface expression in APC and lymphocytes and thereby prevents T cell activation. (A) HIV-1 infec-
tion of macrophages, DCs, and activated lymphocytes was determined 4–5 d after infection by GFP expression, and CD95L expression was determined on 
the GFP+ population for infected cells and on the entire population for noninfected cultures. Results shown are representative of three independent ex-
periments. (B) The percentage of CD95L-expressing cells (left) and the total CD95L expression, defined as the product between percentage of CD95L+ cells 
and mean fluorescence intensity (right), was compared for HIV-1 and HIV-1 Nef*–infected samples, noninfected (n.i.), and isotype control (iso). HIV-1–
infected values were set as 100%. Results shown are a mean of three independent experiments ± the SD. (C) Monocyte-derived macrophages (MDM) JEM VOL. 206, June 8, 2009 
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were infected with HIV-1 IRES-mCherry or left uninfected and stained for surface CD95L 4 d later. Images show CD95L staining below and a merge of 
CD95L (green), mCherry (red), and Nomarski phase contrast above. Bars, 20 µm. (D) MDM infected with HIV-1 IRES-mCherry, HIV-1 Nef* IRES-mCherry 
were separated at day 4 after infection into CD95L+ and CD95L MDM and loaded with SEE. The graphs show the extent of T cell activation after co-
culture of infected CD95L+ and CD95L MDM, or uninfected MDM with Jurkat-NFAT-Luc cells (left) or Jurkat-NFAT-YFP (right). 50 ng/ml PMA/1 µM iono 
and unstimulated Jurkat cells serve as positive and negative control. Each graph represents the mean of three independent experiments performed on 
different blood donors ± SD.
 
detection and elimination by the host immune system. It has 
been previously shown that the accessory HIV-1 Nef protein, 
which is required for effective viral persistence and greatly ac-
celerates progression to AIDS (32), induces CD95L expression 
on T cells (33). HIV-1 also infects macrophages and DCs. 
Thus, Nef-mediated up-regulation of CD95L on APCs to 
suppress T cell responses might represent a novel mechanism 
by which HIV-1 ensures immune evasion. To assess this pos-
sibility, we determined the effect of wild-type and Nef- 
defective HIV-1 infection on surface CD95L expression in 
macrophages and DCs. Monocyte-derived macrophages, DCs, 
and lymphocytes were obtained from healthy blood donors 
and characterized for phenotypic markers immediately before 
infection (Fig. S6). Uninfected cells (mock) or cells infected 
with HIV-1 constructs expressing eGFP alone (Nef-deleted 
HIV-1 Nef*) or together with Nef (wild-type HIV-1) were 
examined for CD95L surface expression 4–5 d after infection. 
Infection rates were typically between 10 and 20% (Fig. 7 A). 
CD95L surface expression was determined on GFP+ HIV-1–
infected cells. For all three cell types, HIV-1 infection consis-
tently enhanced both the percentage of CD95L-expressing 
cells and the levels of cell surface expression by up to two or-
ders of magnitude (Fig. 7 B). Nef significantly contributed to 
induction of CD95L expression in macrophages and lympho-
cytes, but not so in DCs (Fig. 7 B). To directly determine 
whether HIV-induced up-regulation of CD95L on the surface 
of APCs suppresses their capability to stimulate T cells, we ex-
amined the effect of CD95L+ and CD95L macrophages on 
NFAT activation in two different Jurkat lines containing ei-
ther the YFP (Jurkat-NFAT-YFP) or the luciferase (Jurkat-
NFAT-Luc) reporter genes under the control of an NFAT- 
dependent promoter. Both T cell lines express a functional 
TCR and can be stimulated by staphylococcal enterotoxin   
E (SEE) superantigen. This allowed us to measure both the 
overall levels of luciferase activity by plate luminometry as well 
as the proportion of activated YFP+ T cells by flow cytometry. 
To avoid crossover between GFP and YFP fluorescences, we 
infected macrophages with HIV-1 IRES-mCherry viruses and 
verified HIV infection–induced CD95L expression by fluo-
rescent microscopy (Fig. 7 C). After sorting the infected mac-
rophages into CD95L+ and CD95L populations and loading 
with SEE superantigen, we found that HIV-1–infected CD95L 
macrophages caused approximately two- to threefold higher 
levels of T cell activation compared with noninfected macro-
phages (Fig. 7 D). In strict contrast, co-culture with CD95L+-
infected macrophages resulted in levels of NFAT activation 
similar to those observed with uninfected macrophages in both 
readout systems and irrespective of Nef expression. Thus, 
HIV-induced CD95L expression on the surface of macro-
phages clearly suppresses their ability to stimulate T cells. These 
results suggest that the up-regulation of CD95L on APCs by 
HIV-1 to silence T cell activation may suppress immune re-
sponses, facilitate viral immune evasion, and play a role in the 
pathogenesis of AIDS.
DISCUSSION
CD95, which was originally characterized as a death receptor 
inducing apoptosis after CD95L binding, is now increasingly 
recognized as a surface receptor with additional functions apart 
from cell death induction depending on cell type, stimulation, 
and cellular environment. In this study, we demonstrate for the 
first time that co-stimulation of CD95 during T cell activation 
induces inhibition of T cell proliferation in naive T cells by in-
terfering with proximal TCR signaling events, and that CD95 
can act as a silencer of the immune response. This novel role of 
CD95 in down-modulating T cell responses was determined 
in two different systems: (a) an antigen-specific system using 
APCs expressing HLA-A1 and m-CD95L to activate HLA-
A1 T cells and (b) for antigen-independent T cell activation 
with immobilized CD3 and CD28 antibodies in the presence 
of recombinant CD95L. The presence of CD95L during T cell 
activation prevented proliferation of CD4+ and CD8+ T cells 
in both systems. Whereas preactivated CD95-sensitive T cells 
immediately undergo apoptosis after CD95 stimulation, naive 
T cells were inhibited in proliferation. These results appear to 
be in contrast to previous data showing that anti-CD95 anti-
bodies or cross-linked CD95L can augment proliferation of 
CD3-activated primary human T cells (6, 8). However, in 
these experiments, T cell activation was suboptimally induced 
by low concentrations of anti-CD3 antibodies in the absence 
of co-stimulatory signals, and naive and preactivated T cells 
were not analyzed separately. Inhibition of T cell activation by 
CD95L in our system, however, was effective in naive T cells 
activated in the presence of co-stimulation and was indepen-
dent of the strength of the activating signal (Fig. 3 A). Al-
though CD95 triggering induces apoptosis in activated T cells, 
it prevents proliferation during T cell priming in naive T cells, 
indicating that the time point of CD95 triggering determines 
the subsequent fate of the T cell. Dependence on the time 
point of receptor triggering was also reported for signals deliv-
ered via CD95L. Although CD95L may promote reverse sig-
naling and T cell co-stimulation directly after antigen-induced 
CD95L expression, CD95L also mediates apoptosis in T cells 
at the termination phase of the immune response (34).
T cell activation is initiated by the recognition of antigen 
through the TCR and subsequent reorganization of signaling 1390 INHIBITION OF T CELL PRIMING BY CD95 CO-STIMULATION | Strauss et al.
macrophages (49), although the relevance of this effect and the 
impact of Nef remained unclear. In this study, we confirmed 
that HIV infection leads to effective CD95L up-regulation in 
macrophages and T lymphocytes and show for the first time 
that this effect is also observed in DCs. Furthermore, we dem-
onstrate that Nef plays an important role in CD95L enhance-
ment in macrophages and T lymphocytes, but not in DCs, and 
that HIV-induced CD95L expression on macrophages signifi-
cantly prevents the activation of Jurkat T cells. Thus, up-regu-
lation of CD95L expression on APCs by HIV-1 infection 
might contribute to viral immune evasion by inhibiting T cell 
activation and promoting unresponsiveness. This mechanism 
may also have been adopted by other pathogens. Influenza in-
fection in mice induced the expression of CD95L in lymph 
node–resident DCs (50) and up-regulation of CD95L was ob-
served in human DCs after human cytomegalovirus infection 
(51). Interestingly, although human cytomegalovirus–infected 
CD95L-expressing DCs induced apoptosis in activated T cells, 
some T cells survived contact with infected DCs and exhibited 
suppressed proliferation after secondary stimulation in the ab-
sence of the virus (51). This is in line with our observation that 
T cells that have encountered CD95L during T cell priming 
showed decreased proliferation after restimulation. This un-
responsive state was partially reverted by the addition of ex-
ogenous IL-2. Interestingly, lack of anergy induction was also 
reported for CD95-deficient lymphoproliferation mice (52).
On the basis of our findings, we propose a novel role for 
CD95 in naive T cells as a silencer of T cell activation and 
proliferation by down-regulation of TCR signaling upon co-
stimulation. Virus-induced up-regulation of CD95L on the 
surface of APCs may suppress immune responses, and thereby 
support immune evasion and tolerance induction.
MATERIALS AND METHODS
Cell culture. All cell lines were grown in complete RPMI 1640 medium 
(Invitrogen) supplemented with 10% FCS (Lonza), 2 mM l-glutamine, and 
1 mM sodium pyruvate at 37°C in a humidified atmosphere containing 7.5% 
CO2. Establishment of C1R.A1.puro and C1R.A1.CD95L cells were de-
scribed previously (25). T cells were cultured in complete RPMI 1640 me-
dium supplemented with 2% FCS.
T cells were isolated from PBMCs of healthy HLA-A1 donors by Ro-
setteSep (StemCell Technologies). Institutional ethic committee approved 
the usage of buffy coats for T cell isolation. Purity varies between 92–97%. 
Naive T cells were separated from the T cell pool by using anti-CD45RO 
(Cl. UCHL1) and anti-CD25 (Cl. M-A251; BD) antibodies, and subsequent 
incubation with Dynabeads goat anti–mouse IgG (Invitrogen). Purity was 
determined by flow cytometry using CD45RA-FITC (Cl. ALB11; Immuno-
tech) and ranged between 90–97%. For proliferation assays and cytokine   
assays, plates were coated with 0.1 µg/ml anti-CD3 (cl. OKT3) and 0.1 µg/ml 
anti-CD28 (cl.15E8). In all other assays, 0.25 µg/ml OKT3 and 0.25 µg/ml 
15E8 were used. To trigger CD95, we used 2 µg/ml immobilized recombi-
nant CD95L (Alexis Biochemicals) or 2 µg/ml Fc-CD95L supernatant pro-
vided by H. Walczak (Imperial College London, London, UK) (53). For 
TCR-independent T cell activation, we used 0.8 ng/ml PMA (Calbiochem) 
and 20 nM ionomycin (Calbiochem). CFSE-labeled HLA-A1 T cells were 
stimulated with medium or mitomycin c–treated C1R.A1.puro or C1R.
A1.CD95L cells at a ratio of 1:1.
For HIV infection experiments, monocytes were separated from PBMCs 
of healthy donors by plastic adherence. PBLs were activated for 3 d with   
molecules into lipid rafts. Although productive T cell activa-
tion induced translocation of ZAP-70, PKC-, and PLC- 
into lipid rafts, triggering CD95 during T cell activation pre-
vented their recruitment. However, molecules constitutively 
associated with rafts, such as LAT and lymphocyte-specific ki-
nase (35), were recruited, indicating that CD95 triggering does 
not induce a global change in raft composition. The mecha-
nism by which CD95 signaling prevents translocation of TCR-
associated molecules into the signaling platform remains elusive. 
Changes in the composition of raft-associated molecules were 
also observed in anergic T cells, where LAT could not be re-
cruited to lipid rafts because of a selective palmitoylation defect 
(36), or upon anti-CD4 antibody treatment, which inhibited 
ZAP-70 translocation into lipid rafts, thereby preventing NF-B   
activation (37). Steric hindrance of TCR signaling by recruit-
ment of CD95 into lipid rafts after CD95 co-stimulation did 
not account for the inhibition of T cell proliferation, as no   
increase of CD95 in lipid rafts was detected in CD95L-treated 
T cells (unpublished data). The inhibitory effect of CD95 trig-
gering on T cell activation was also analyzed on downstream 
events. Thus, protein tyrosine phosphorylation of ZAP-70, 
LAT, and PLC-1 was totally inhibited in the presence of 
CD95L. We further observed a significant decrease in Ca2+-
mobilization and inefficient nuclear translocation of transcrip-
tion factors NF-B, AP-1, and NFAT in T cells triggered by 
CD95 during T cell activation. Impaired activation of NF-B, 
AP-1, and NFAT was confirmed by the reduced expression of 
activation markers and a decrease in cytokine secretion. CD95 
co-stimulation during T cell priming also prevents MAPK and 
caspase activation, both known to be required for efficient   
T cell activation (8, 28). Block of calcium channel, Ca2+ mobili-
zation, and NFAT activation caused by activation of acidic 
sphingomyelinase and ceramide release was also observed in   
T cells stimulated by CD95 alone (38).
Our data add a new function to the already known role of 
CD95 in apoptosis induction and T cell proliferation (7) by 
defining CD95 as a T cell silencer. The newly identified   
immunosuppressive function of CD95 co-stimulation might 
point to a role of elevated CD95L serum levels in several types 
of cancers (39–41) or might explain the requirement for CD95L 
expression on veto cells (42). In the murine system, CD95L 
expression on veto cells was predominantly correlated with 
apoptosis induction of CD95+ T cell precursors (42–44). How-
ever, whereas naive murine T cells are constitutively CD95 
sensitive (45), naive human T cells are CD95 resistant (26). 
Therefore, human veto cells may not only induce apoptosis, 
but may additionally interfere with T cell activation. Although 
CD95L is predominantly expressed on T cells and NK cells, 
expression of CD95L was reported in human immature blood 
DCs, blood monocytes, or activated Langerhans cells (46, 47). 
Our findings suggest that CD95L expression on APCs might 
represent a novel mechanism to silence T cells and to support 
immune evasion. It is known that the HIV-1 Nef up-regulates 
CD95L in infected T lymphocytes, possibly to induce apopto-
sis of bystander cytotoxic T cells (33, 48). It has also been 
shown that HIV-1 infection leads to CD95L up-regulation in JEM VOL. 206, June 8, 2009 
ARTICLE
1391
software were used. For image analysis, the cells were digitally outlined and the 
mean fluorescence intensity was determined for each cell at each single time 
point (ImageJ software). After subtracting the background fluorescence, the 
mean fluorescence intensity of all cells at each time point was determined.
Determination of cytokine concentrations in cell culture supernatants. 
T cells were cultured in medium alone or activated with stimulator cells at a ratio 
of 1:1 or with antibodies and recombinant CD95L. Supernatants were collected 
at the indicated time points and immediately stored at 80°C. All supernatants 
were analyzed simultaneously by Immuned GmbH using Bio-Plex technology.
Nuclear protein extraction and electrophoretic mobility shift assay. 
Purified T cells were activated with immobilized antibodies and recombinant 
CD95L or with 10 ng/ml PMA and 500 nM ionomycin for 1 h. Nuclear ex-
tracts and electrophoretic mobility shift assays (EMSAs) were performed as 
previously described (54). For EMSA, the following oligonucleotides were 
used: NF-B, 5-AGTTGAGGGGACTTTCCCAGGC-3 (sense); NF-AT, 
5-TCTAAGAGGAAAATTTCATG-3 (sense); AP-1, 5-CGCTTGAT-
GAGTCAGCCGGAA-3 (sense).
Analysis of protein tyrosine phosphorylation. Purified T cells were serum 
starved overnight in complete medium supplemented with 0.5% FCS, and   
subsequently activated on antibody-coated plates and lysed in 50 mM Hepes, 
100 mM NaCl, 1% IGEPAL CA-630, 1% laurylmaltoside, 1 mM PMSF, 5 mM 
EDTA, 1 mM Na3VO4, 50 mM NaF, and 10 mM Na4O7P2 × 10 H2O for   
15 min, and protein lysates were subjected to Western blot analysis.
Isolation of lipid rafts. T cells were lysed in 50 mM Hepes, 100 mM naCl, 
3% Brij 58, 1 mM PMSF, 5 mM EDTA, 1 mM Na3VO4, 50 mM NaF, and   
10 mM Na4O7P2 × 10 H2O for 10 min on ice. The lysate was mixed 1:1 with 
ice-cold 80% sucrose diluted in 25 mM MES, 5 mM EDTA, and 150 mM 
NaCl, transferred to Ultra-Clear centrifuge tubes (Beckman Coulter), and over-
laid with ice-cold 30% sucrose, followed by ice-cold 5% sucrose. After centrifu-
gation in a Beckman Coulter SW41 rotor, 40,000 rpm, for 20 h at 4°C, 11 
1-ml-fractions were collected and subjected to aceton precipitation.
Western blot analysis. Western blot analysis was described previously (55). 
The following antibodies were used: anti-phosphotyrosine (cl. 4G10), LAT 
(cl. 2E9) (Millipore), phospho-PLC1 (Tyr783), phospho-LAT (Tyr191), 
phospho-Zap-70(Tyr319)/Syk(Tyr352),  caspase-3,  PARP,  PLC1  (Cell 
Signaling  Technology),  ZAP  70  (cl.  29),  PKC-  (cl.  27),  JNK1/JNK2 
(G151-666; BD), -actin (AC-15), ERK-1/ERK2 (Sigma-Aldrich), cas-
pase-8  (12F5;  Alexis),  caspase-10  (cl.  4C1;  MBL),  ERK1/2(phospho-
Thr202/Tyr204),  p38  MAPK  (phospho-Thr180/Tyr182;  Assay  Design), 
anti-active JNKpAb (Promega), p38 (Stressgen) goat anti–mouse IgG-HRP, 
goat ant–rabbit IgG –HRP, SH-PTP1 (C-19), and SH-PTP2 (B-1; Santa 
Cruz Biotechnology, Inc.).
Online supplemental material. Fig. S1 compares the expression of CD95L 
on naive and activated human T cells. Fig. S2 compares inhibition of T cell 
proliferation by CD95 co-stimulation in CD4+ and CD8+ T cells cultured 
isolated or together. Fig. S3 shows that soluble CD95L could not reverse the 
inhibitory effect of immobilized CD95L during T cell activation. Fig. S4 shows 
the expression of LAT and -tubulin in fractions derived from discontinuous 
sucrose gradients. Fig. S5 depicts the expression of TCR-associated molecules 
in raft and nonraft fractions of unstimulated and CD95L-stimulated T cells. 
Fig. S6 shows the phenotype of primary macrophages, DC, and lymphocytes 
before HIV infection. The online supplemental material is available online at 
http://www.jem.org/cgi/content/full/jem.20082363/DC1.
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10 µg/ml PHA before infection. Monocytes were differentiated into imma-
ture DCs by culturing for 5 d with 50 ng/ml recombinant human GM-CSF 
and 20 ng/ml IL4 (Immunotools) or into macrophages by culturing for 7 d 
with 50 ng/ml human recombinant GM-CSF alone. Phenotypic character-
ization before infection was done by flow cytometry using CD3, CD4, 
HLA-DR, CD14, CD1a, CD80, and CD86 antibodies (BD).
Virus  production  and  infection.  Wild-type  NL43-Nef-IRES-GFP  or 
NL43-Nef-IRES-mCherry (referred to as HIV-1) and Nef-deleted NL43-
Nef*-IRES-GFP or NL43-Nef*-IRES-mCherry (referred to as HIV-1 Nef*) 
viruses were produced by transient calcium phosphate cotransfection of 293T 
cells with proviral plasmid and an expression plasmid for the vesicular stomati-
tis envelope glycoprotein following standard protocols. Cell supernatants con-
taining virions were collected at 48 h after transfection and used immediately 
to infect PBL, immature DCs, or macrophages and replaced after 3 h for 
monocyte-derived cells (or after 6 h for PBLs) by RPMI medium with the 
appropriate cytokines.
Microscopy. Macrophages grown on glass coverslips were stained for surface 
CD95L (NOK-1) followed by goat anti–mouse Alexa Fluor 647 (Invitrogen) at 
4 dpi and analyzed by Apotome structured illumination fluorescent microscopy 
using an Axiovert microscope equipped with a Plan-Apochromat 63×, NA 1.4, 
oil objective and a MRm charge-coupled device camera piloted by Axiovision 
software (all from Carl Zeiss, Inc.).
Activation of Jurkat-NFAT by HIV-infected macrophages. Infected 
macrophages labeled with anti-CD95L mAb (NOK-1) followed by rat anti–
mouse microbeads (Miltenyi Biotec) were isolated into CD95L+ and CD95L 
populations by MACS according to the manufacturer’s instructions. CD95L+ 
and CD95L macrophages were loaded with 1 µg/ml SEE superantigen (Toxin 
Technology) and placed in co-culture at a 1:2 ratio with Jurkat-NFAT-Luc cells 
or with Jurkat-NFAT-YFP cells. After 6 h, Jurkat-NFAT-Luc cells were lysed 
and tested for luciferase by plate bioluminescence using the Promega Luciferase 
Assay System according to the manufacturer’s instructions. Jurkat-NFAT-YFP 
cells were fixed and analyzed by flow cytometry for YFP expression. Incubation 
was restricted to a 6-h period to avoid interference with CD95-mediated apop-
tosis in Jurkat targets.
Flow cytometry. In general, 5 × 105 cells were stained with the following anti-
bodies: CD25-PE, CD69-PE, CD71-FITC, CD95-FITC, HLA-DR, DP, DQ-
FITC, CD95L (NOK-1), CD2-APC, CD3-PE, CD4-PE, CD4-Pacific blue, 
CD8-PE, CD8-FITC, CD8-PE-Cy-7 (BD), CD4-PE-Cy5.5 (Caltag), and 
goat anti–mouse F(ab)2-PE (Dako). Dead cells were visualized using 1 µg/ml 
propidium iodide (Sigma-Aldrich) or 1 µg/ml 7-amino-actinomycin-D (AAD; 
Sigma-Aldrich). To measure caspase activity fluorometrically, T cells were incu-
bated with a 100-µM solution of the rhodamine 110-based, cell membrane– 
permeable caspase substrates DEVD or IETD (Invitrogen). Analysis was done on 
FACScan or LSR II flow cytometer (BD).
CFSE labeling. 2 × 106 T cells/ml were labeled with 100 µl of 50 µM CFSE 
(Cell Trace CFSE Cell proliferation kit; Invitrogen) for 10 min at 37°C. Cells 
were immediately washed 4 times with ice-cold PBS-5% FCS and subsequently 
used for proliferation assays.
Measurement of intracellular calcium. T cells were labeled for 20 min at 
37°C with 1 µM Fluo-4 and seeded on poly-l-lysine–coated slides (POLY-
PRE slides; Sigma-Aldrich). Nonadherent cells were washed away and anti-
bodies were given to cells directly before the measurement. Recombinant 
CD95L was preincubated for 15 min at 37°C before adding CD3 and CD28 
antibodies. To measure the intracellular calcium increase, we recorded a time 
series (duration, 6 min; interval, 1 s) of one confocal image plane. Images were 
acquired with an Infinity multibeam confocal device (Visitron) mounted be-
tween an Axiovert 200 and a charge-coupled device camera (CascadeII 512). 
Fluo-4 was excited with a 488-nm Argon/Krypton laser and detected with a 
500–550-nm emission filter. A 10× plan Neofluar objective and Metamorph 1392 INHIBITION OF T CELL PRIMING BY CD95 CO-STIMULATION | Strauss et al.
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